From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis - Top-Institutions - MDSpire

From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis

  • By

  • Michalina Horochowska

  • Ewa Jakubczyk

  • Marek Ussowicz

  • June 19, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, California

    Key Differentiators

    • Pediatrics

  • #2

    St. Jude Children’s Research Hospital
    St. Jude Children’s Research Hospital

    Memphis, Tennessee

    Key Differentiators

    • Pediatrics

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Pediatrics

  • #4

    Levine Cancer Institute
    Levine Cancer Institute

    Charlotte, North Carolina

    Key Differentiators

    • Pediatrics

  • #5

    Children’s Hospital Colorado
    Children’s Hospital Colorado

    Aurora, Colorado

    Key Differentiators

    • Pediatrics

Original Source(s)

From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis

  • by Michalina Horochowska, Ewa Jakubczyk, Marek Ussowicz

  • June 19, 2026

Related Content

FOXI3 promotes migration and proliferation in prostate cancer bone metastases, modulated by FGF8

The quiet joy of being an oncologist

Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential